Bergamo Lymphoid Cancer Registry
Launched by A.O. OSPEDALE PAPA GIOVANNI XXIII · Apr 24, 2017
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Bergamo Lymphoid Cancer Registry is a research study aimed at understanding more about lymphoid cancers, which include Hodgkin lymphoma, non-Hodgkin lymphoma, and myeloma. By collecting information from patients, the study hopes to learn about the different characteristics and outcomes of these cancers, helping doctors improve treatment in the future. The trial is currently looking for participants who are at least 18 years old and have a confirmed diagnosis of one of these cancers.
If you or someone you know is interested in participating, you would need to provide written consent and meet the eligibility criteria. The study is open to everyone regardless of gender. By joining, participants can help contribute valuable information that could benefit future patients with similar conditions. It's also important to note that individuals with an unconfirmed diagnosis will not be able to participate.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female patients 18 years or older
- • Written informed consent
- • Confirmed diagnosis of Hodgkin disease, non-Hodgkin lymphomas or myeloma
- Exclusion Criteria:
- • - Unconfirmed diagnosis of Hodgkin disease, non-Hodgkin lymphomas or myeloma
About A.O. Ospedale Papa Giovanni Xxiii
A.O. Ospedale Papa Giovanni XXIII is a prestigious healthcare institution dedicated to advancing medical research and improving patient care through innovative clinical trials. Located in Bergamo, Italy, the hospital is renowned for its commitment to excellence in various medical specialties, fostering a collaborative environment that integrates cutting-edge science with compassionate healthcare. The institution actively engages in clinical research to evaluate new therapies and treatment protocols, aiming to enhance health outcomes and contribute to the global medical community's knowledge base. With a focus on patient safety and ethical standards, A.O. Ospedale Papa Giovanni XXIII plays a vital role in shaping the future of medicine through rigorous and impactful clinical investigations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bergamo, , Italy
Patients applied
Trial Officials
Alessandro Rambaldi, MD
Principal Investigator
A.O. Ospedale Papa Giovanni XXIII
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials